Trial reportPloS one2013
Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 130 citations in OpenAlex.
- Trial
- Novel metabolic markers for the risk of diabetes development in American Indians.Diabetes care · 2015Trial
- Serum L-ornithine-derived polyamines as indicators of Parkinson disease progression.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Effects of Exposure to Ambient Air Pollution on Human Metabolome in Patients with Coronary Artery Disease.Environmental science & technology · 2025Article
- Urinary metabolomic profiling in 22q11.2 deletion syndrome reveals microbial and mitochondrial signatures related to autism and psychosis risk.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Enrichment of gut-derived metabolites in a Parkinson's disease subtype with REM sleep behavior disorder.NPJ Parkinson's disease · 2025Article
- Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Metabolomics in Parkinson's Disease and Correlation with Disease State.Metabolites · 2025Review
- Protocols for Metabolomic Analyses to Assess Changes in Central Carbon Metabolism from Neural Tissue.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Integrating digital gait data with metabolomics and clinical data to predict outcomes in Parkinson's disease.NPJ digital medicine · 2024Article
- Article
- Metabolomic signatures of ideal cardiovascular health in black adults.Scientific reports · 2024Article
- ALTERATIONS IN HISTIDINE METABOLISM IS A FEATURE OF EARLY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD).Transactions of the American Clinical and Climatological Association · 2024Article
- The Molecular Role of Polyamines in Age-Related Diseases: An Update.International journal of molecular sciences · 2023Review
- Review
- Oxidative stress-induced phosphorylation of JIP4 regulates lysosomal positioning in coordination with TRPML1 and ALG2.The EMBO journal · 2022Article
- Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.Brain : a journal of neurology · 2022Article
- Serum Metabolomic Analysis of Male Patients with Cannabis or Amphetamine Use Disorder.Metabolites · 2022Article
- Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Progression of Parkinson's disease (PD) is highly variable, indicating that differences between slow and rapid progression forms could provide valuable information for improved early detection and management. Unfortunately, this represents a complex problem due to the heterogeneous nature of humans in regards to demographic characteristics, genetics, diet, environmental exposures and health behaviors. In this pilot study, we employed high resolution mass spectrometry-based metabolic profiling to investigate the metabolic signatures of slow versus rapidly progressing PD present in human serum. Archival serum samples from PD patients obtained within 3 years of disease onset were analyzed via dual chromatography-high resolution mass spectrometry, with data extraction by xMSanalyzer and used to predict rapid or slow motor progression of these patients during follow-up. Statistical analyses, such as false discovery rate analysis and partial least squares discriminant analysis, yielded a list of statistically significant metabolic features and further investigation revealed potential biomarkers. In particular, N8-acetyl spermidine was found to be significantly elevated in the rapid progressors compared to both control subjects and slow progressors. Our exploratory data indicate that a fast motor progression disease phenotype can be distinguished early in disease using high resolution mass spectrometry-based metabolic profiling and that altered polyamine metabolism may be a predictive marker of rapidly progressing PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.